Read by QxMD icon Read

Bone Metastases Prostate cancer

Erica Campagnaro, Melissa A Reimers, Angel Qin, Ajjai S Alva, Bryan J Schneider, Catherine H Van Poznak
The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval of zoledronic acid may be extended from every 4 weeks to every 12 weeks. The ASCO guidelines on the role of bone-modifying agents in metastatic breast cancer and multiple myeloma address zoledronic acid dosing intervals...
August 2018: Journal of Oncology Practice
Michael J Seider, Stephanie L Pugh, Corey Langer, Gwen Wyatt, William Demas, Afshin Rashtian, Cathy L Clausen, Jerome David Derdel, Sean F Cleary, Christopher A Peters, Ashok Ramalingam, James E Clarkson, Michael Tomblyn, Rachel A Rabinovitch, Lisa A Kachnic, Lawrence B Berk
BACKGROUND: Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. METHODS: NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153). The primary endpoint was time to development of SREs...
August 9, 2018: Annals of Nuclear Medicine
A Juárez-Soto, J M Garín-Ferreira, A Rodríguez-Fernández, J L Tirado-Hospital, M T González-Serrano, J Moreno-Jiménez, R Medina-López, V Baena-González
INTRODUCTION: In castration-resistant prostate cancer (CRPC), early detection of metastases is essential for the selection of treatment, and prevention of bone complications. However detecting incipient metastases remains a challenge as the conventional radiological tests (bone scintigraphy or computerised tomography) lack sufficient sensitivity. Diagnostic imaging techniques are currently available that have greater sensitivity and specificity, but are little used due to shortfalls in the recommendations...
August 3, 2018: Actas Urologicas Españolas
Ciro Franzese, Paolo Andrea Zucali, Lucia Di Brina, Giuseppe D'Agostino, Pierina Navarria, Davide Franceschini, Armando Santoro, Marta Scorsetti
BACKGROUND: Diagnoses of oligometastatic prostate cancer (PC) increased in the recent years thanks to the advancement in imaging and more effective systemic therapies. Here we evaluate the efficacy of Stereotactic Body Radiation Therapy (SBRT) in oligorecurrent and oligoprogressive PC. METHODS: We included patients with a maximum of five metastases diagnosed in a maximum of two target organs. Concomitant treatment with hormonal therapies or chemotherapies was allowed...
August 2, 2018: Cancer Medicine
Francesco Fiz, Helmut Dittman, Cristina Campi, Silvia Morbelli, Cecilia Marini, Massimo Brignone, Matteo Bauckneht, Roberta Piva, Anna Maria Massone, Michele Piana, Gianmario Sambuceti, Christian la Fougère
Metastasized castration-resistant prostate cancer (mCRPC), is the most advanced form of prostate neoplasia, where massive spread to the skeletal tissue is frequent. Patients with this condition are benefiting from an increasing number of treatment options. However, assessing tumor response in patients with multiple localizations might be challenging. For this reason, many computational approaches have been developed in the last decades to quantify the skeletal tumor burden and treatment response. In this review, we analyzed the progressive development and diffusion of such approaches...
July 28, 2018: Bioengineering
Diego Iglesias-Gato, Elin Thysell, Stefka Tyanova, Sead Crnalic, Alberto Santos, Thiago S Lima, Tamar Geiger, Juergen Cox, Anders Widmark, Anders Bergh, Matthias Mann, Amilcar Flores-Morales, Pernilla Wikström
BACKGROUND: Bone is the most predominant site of distant metastasis in prostate cancer(PCa) and patients have limited therapeutic options at this stage. EXPERIMENTAL DESIGN: We performed a system-wide quantitative proteomic analysis of bone metastatic prostate tumors from 22 patients operated to relief spinal cord compression. At the time of surgery, most patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated. An extended cohort of prostate cancer bone metastases (n=65) was used for immunohistochemical validation...
July 24, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Frederik L Giesel, Karina Knorr, Fabian Spohn, Leon Will, Tobias Maurer, Paul Flechsig, Oliver Neels, Kilian Schiller, Horacio Amaral, Wolfgang Weber, Markus Schwaiger, Markus Hohenfellner, Clemens Kratochwil, Juergen Debus, Uwe Haberkorn, Peter Choyke, Vasko Kramer, Klaus Kopka, Matthias Eiber
Recently, prostate-specific membrane antigen (PSMA) targeted PET-imaging has emerged as new method of staging and restaging of prostate cancer. Most published studies have investigated the diagnostic potential of 68 Ga-labeled PSMA-agents which are excreted renally. [18 F]PSMA-1007 is a novel PSMA-ligand with excellent preclinical characteristics which is only minimally excreted by the urinary tract, a potential advantage for pelvic imaging. The aim of this study was to investigate the diagnostic efficacy of [18 F]PSMA-1007 in biochemical recurrence (BCR) after radical prostatectomy (RP)...
July 24, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
F Gómez-Veiga, J L Álvarez-Ossorio, J Carballido-Rodríguez, A Juárez-Soto, A Rodríguez-Antolín, J M Cozar-Olmo
CONTEXT: The elimination of bone metastases, restoration and/or preservation of bone morphology and prevention and/or delay of skeletal events are a fundamental objective in the management of metastatic castration-resistant prostate cancer (mCRPC). Radium-223 is the first targeted alpha therapy with effects on bone that has been shown to increase survival in these patients, besides providing other bone-related benefits. OBJECTIVE: To analyze the impact of bone metastasis on mCRPC, and the benefits and the window of opportunity provided by radium-223 in the treatment of patients with mCRPC in the current treatment era...
July 2, 2018: Actas Urologicas Españolas
Konstantin Kolontarev, Alexander Govorov, George Kasyan, Paul Rasner, Alexander Vasiliev, Dmitry Pushkar
Introduction: Biochemical relapse (BR) after a primary radical prostatectomy may occur in up to 40 percent of cases. Salvage lymphadenectomy has been proposed in patients with 'node-only' driven BR, following a definitive treatment of primary prostate cancer (PCa). We present our initial series of 10 consecutive patients who underwent an extended robotic salvage pelvic lymph node dissection (eRSPLND) for 'node-only' recurrent PCa. Materials and methods: It was a prospective study, including patients who presented with biochemical relapse after a primary radical prostatectomy at a median of 3...
2018: Central European Journal of Urology
Masha Maharaj, Nisaar Korowlay
Skeletal involvement occurs in 30%-70% of all cancer patients, with breast cancer (BC) being the leading cause for bone metastases in women and prostate cancer in men followed by lung cancer. Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome. It is yet unknown what is the impact of HIV to the onset and progression of bone disease in BC. The purpose of the study was to determine the association of HIV infection and skeletal metastases in BC using skeletal scintigraphy...
July 2018: World Journal of Nuclear Medicine
Christian Daniel Fankhauser, Cédric Poyet, Stephanie G C Kroeze, Benedikt Kranzbühler, Helena I Garcia Schüler, Matthias Guckenberger, Philipp A Kaufmann, Thomas Hermanns, Irene A Burger
PURPOSE: To review the current literature and discuss potential future roles of the novel positron emission tomography (PET) tracers targeting the prostate-specific membrane antigen (PSMA) in patients with castration-resistant prostate cancer (CRPC). METHODS: A literature search on February 19th 2018 was conducted using the Medline database and . Additionally, illustrative cases of CRPC patients from our own institution who were restaged and treated based on PSMA-PET scan results are provided...
July 20, 2018: World Journal of Urology
Avinash Kumar, Swati Dhar, Gisella Campanelli, Nasir A Butt, Jason M Schallheim, Christian R Gomez, Anait S Levenson
Prostate cancer often metastasizes to the bone, leading to morbidity and mortality. While metastasis-associated protein 1 (MTA1) is highly overexpressed in metastatic tumors and bone metastatic lesions, its exact role in the development of metastasis is unknown. Here, we report the role of MTA1 in prostate cancer progression and bone metastasis in vitro and in vivo. We found that MTA1 silencing diminished formation of bone metastases and impaired tumor growth in intracardiac and subcutaneous prostate cancer xenografts, respectively...
July 20, 2018: Molecular Oncology
Weiwei Shen, Hailin Pang, Bo Xin, Lian Duan, Lili Liu, Helong Zhang
Small-cell lung cancer (SCLC) is typically fatal if untreated. It is characterized by early and widespread metastases, and has the ability to rapidly develop resistance to chemotherapy. Bone morphogenetic protein 7 (BMP7), a member of the BMP family of signaling molecules, has been implicated in various types of cancer, particularly prostate cancer and breast cancer. However, there is little knowledge of the function of BMP7 in SCLC. The aim of the present study was to investigate the biological function of recombinant human (rh)BMP7 on SCLC cells and the underlying molecular basis for this regulatory mechanism...
September 2018: International Journal of Oncology
Samer L Traboulsi, Fred Saad
PURPOSE OF REVIEW: The widespread use of prostate-specific antigen (PSA) resulted in stage migration of prostate cancer where androgen deprivation therapy (ADT) is administered for biochemical recurrence in patients following primary treatment. A proportion of these patients progress to a disease state termed nonmetastatic castration-resistant prostate cancer (nmCRPC), with a rising PSA despite ADT and without evidence of metastases on conventional imaging. We will review the treatment options in nmCRPC, especially in light of recent trials showing significant improvement in metastasis-free survival with newer agents...
September 2018: Current Opinion in Supportive and Palliative Care
Gul Ege Aktas, Vuslat Yürüt Çaloğlu, Hakan Akdere, Busem Binboğa Tutuğ, Gülay Durmuş Altun
Prostate adenocarcinoma (PCa) is the most frequently diagnosed malignancy in the male population, with the most common sites for secondary lesions being the lymph nodes, bones, and lungs. Testicular metastases from PCa are very rare and mostly identified incidentally after therapeutic orchiectomy for advanced PCa or during autopsy. Here we present a case involving a 64-year-old man with biochemical recurrence of castrated oligometastatic PCa that presented as solitary testicular metastasis on Ga-PSMA ligand positron emission tomography/computed tomography...
September 2018: Clinical Nuclear Medicine
Thambi Dorai, Ankeeta Shah, Faith Summers, Rajamma Mathew, Jing Huang, Tze-Chen Hsieh, Joseph M Wu
In the course of studies aimed at the role of oxidative stress in the development of metastatic potential in the LNCaP-C4-2B prostate cancer progression model system, we found a relative decrease in the level of expression of the cytoplasmic nicotinamide riboside: quinone oxidoreductase (NQO2) and an increase in the oxidative stress in C4-2B cells compared to that in LNCaP or its derivatives C4 and C4-2. It was also found that C4-2B cells specifically shed large extracellular vesicles (LEVs) suggesting that these LEVs and their cargo could participate in the establishment of the osseous metastases...
July 15, 2018: Prostate
Shuangli Zhang, Baolin Li, Wei Tang, Linying Ni, Huili Ma, Ming Lu, Qinggang Meng
Previous studies have demonstrated that connective tissue growth factor (CTGF) is expressed at increased levels in prostate cancer bone metastasis mouse models and patients with prostate cancer which metastasizes to the bone; however, the underlying molecular mechanism(s) remain unknown. The present study investigated the function of CTGF in osteoblast differentiation and its effect on prostate cancer bone metastasis by analyzing CTGF gene expression and transcription at different levels of invasion, metastasis of prostate cancer cells, and the influence of CTGF on proliferation and xenotransplantation...
August 2018: Oncology Letters
Halil Komek, Canan Can, Ugur Yilmaz, Serdar Altindag
OBJECTIVE: To determine the association of 68 Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancer patients. METHODS: A total of 148 consecutive patients mean age: 69.3 ± 7.8 years with advanced prostate cancer who underwent 68 Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded...
July 13, 2018: Annals of Nuclear Medicine
A M García Vicente, B González García, M Amo-Salas, I García Carbonero, J Cassinello Espinosa, J L Gómez-Aldaraví Gutierrez, L Suarez Hinojosa, Á Soriano Castrejón
AIM: To establish the utility of baseline 18 F-Fluorocholine (FCH) PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with 223 Ra. METHODS: Prospective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation of 223 Ra (basal FCH PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT...
July 13, 2018: Clinical & Translational Oncology
Janine Hensel, Antoinette Wetterwald, Ramzi Temanni, Irene Keller, Carsten Riether, Gabri van der Pluijm, Marco G Cecchini, George N Thalmann
Prostate and breast cancers frequently metastasize to bone. The physiological bone homeostasis is perturbed once cancer cells proliferate at the bone metastatic site. Tumors are complex structures consisting of cancer cells and numerous stroma cells. In this study, we show that osteolytic cancer cells (PC-3 and MDA-MB231) induce transcriptome changes in the bone/bone marrow microenvironment (stroma). This stroma transcriptome differs from the previously reported stroma transcriptome of osteoinductive cancer cells (VCaP)...
June 22, 2018: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"